ALK and lung adenocarcinoma: In a recent study of lung adenocarcinomas, mutation rates for EGFR (39%), KRAS (4%), ALK (15%), and HER2 (5%) in never-smoker groups differed from rates in current or former smoker groups (10%, 35%, 4%, and 1%, respectively) [21].